Clinical Trial Update: Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab Therapy [Phase 1]

View source ↗

Summary

This trial update reports the completion of a Phase 1 study evaluating the combination of Alvespimycin (KOS-1022) with trastuzumab, with or without paclitaxel, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Solid Tumors

Drugs mentioned

• Alvespimycin (KOS-1022) (alvespimycin)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Solid Tumor, Breast Cancer | Phase 1 | Status: COMPLETED